Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 2/20 | 0.41 |
| ▸ | SI | P14410 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxyphenisatin Acetate SCHEMBL29737232 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| Oxyphenisatin Acetate SCHEMBL7528210 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| SCHEMBL11748297 | 0.94 | MAPT (0.88) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| SCHEMBL23514397 | 0.91 | MAPT (0.83) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| SCHEMBL11748296 | 0.90 | MAPT (0.81) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| Oxyphenisatin Acetate SCHEMBL6752189 | 0.87 | MAPT (0.76) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| SCHEMBL13145376 | 0.84 | MAPT (0.73) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| SCHEMBL11751534 | 0.82 | MAPT (0.70) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| SCHEMBL30226150 | 0.82 | MAPT (0.70) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 | |
| SCHEMBL5483660 | 0.82 | MAPT (0.70) | MAPTSMN1; SMN2CHRM2ADORA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4470620-A2 | OXYPHENISATIN ACETATE, OXYPHENISATIN AND BISACODYL FOR TREATING TRIPLE-NEGATIVE BREAST CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-12-04 | — | — | EP | claimed |
| EP-3749302-B1 | OXYPHENISATIN ACETATE, OXYPHENISATIN AND BISACODYL FOR TREATING TRIPLE-NEGATIVE BREAST CANCER | US HEALTH (US) | 2024-10-23 | — | — | EP | claimed |
| US-20210220329-A1 | A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER | DANA FARBER CANCER INSTITUTE | 2021-07-22 | — | — | US | claimed |
| EP-3749302-A1 | A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2020-12-16 | — | — | EP | claimed |
| WO-2019157300-A1 | A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-08-15 | — | — | WO | claimed |
| CN-109218875-A | The intelligent Headphone device personalization system and application method of tool orientation talk function | 赵平 | 2019-01-15 | — | — | CN | claimed |
| CN-109218876-A | There are the intelligent Headphone device personalization system and application method of the outgoing function of safety | 赵平 | 2019-01-15 | — | — | CN | claimed |
| CN-108891568-A | A kind of gas-turbine unit based on light guide techniques | 余达辉 | 2018-11-27 | — | — | CN | claimed |
| CN-207369231-U | The initialization system of multifunctional intelligent Headphone device | 赵平 | 2018-05-15 | — | — | CN | claimed |
| CN-102529979-B | The mode automatic selection method of in-vehicle electronic system | 上海博泰悦臻电子设备制造有限公司 | 2016-06-22 | — | — | CN | claimed |
| CN-102529979-A | Automatic mode selecting method of vehicle-mounted electronic system | SHANGHAI PATEO YUEZHEN ELECT | 2012-07-04 | — | — | CN | claimed |
| CN-102541415-A | Mode switching method for vehicle-mounted electronic system | SHANGHAI PATEO YUEZHEN ELECT | 2012-07-04 | — | — | CN | claimed |
| US-8026285-B2 | Control release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-09-27 | — | — | US | claimed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | claimed |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | claimed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | claimed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | claimed |
| CN-1067355-A | A kind of mouse attractant and preparation method thereof | LOU LIANGSHUI (CN) | 1992-12-30 | — | — | CN | claimed |
| EP-0229058-A1 | VIDEO HOLOGRAPHIC GENERATION (VHG) AND ANGLED SQUARE LENS REFRACTION | LADY BEA ENTERPRISES INC. (US) | 1987-07-22 | — | — | EP | claimed |
| WO-1987000716-A1 | VIDEO HOLOGRAPHIC GENERATION (VHG) AND ANGLED SQUARE LENS REFRACTION | LADY BEA ENTERPRISES, INC. (US) | 1987-01-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | MAPT 869/4885SMN1; SMN2 3010/4885CHRM2 3388/4885 |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | MAPT 1785/4885SMN1; SMN2 234/4885CHRM2 2994/4885 |
| US-20210220329-A1 | A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER | BRCA1, OPRL1, TPD52L2 | MAPT 506/4885SMN1; SMN2 4005/4885CHRM2 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.